Alexander G. Raufi, MD, is an Assistant Professor of Medicine at the Warren Alpert Medical School of Brown University, a hematologist/oncologist at the Lifespan Cancer Institute at The Miriam and Rhode Island Hospitals, where he specializes in Gastrointestinal Oncology, and is the Director of the Gastrointestinal Clinical Trials Program at Lifespan Cancer Institute. Dr. Raufi received his medical degree from The Warren Alpert Medical School of Brown University. He completed his residency training in internal medicine at the University of California, Irvine in Orange, California, and his fellowship training in hematology/oncology at Columbia University/New York-Presbyterian in New York, New York.
Dr. Raufi conducts both laboratory and clinical research at Brown University and Lifespan Cancer Institute. His research interests include the development of novel immunotherapy combinations in gastrointestinal malignancies and the development of preventive strategies for gastrointestinal cancers. He is a recipient of a 2019 Young Investigator Award from the Conquer Cancer Foundation/American Society of Clinical Oncology. Dr. Raufi is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.
Raufi AG, May MS, Hadfield MJ, Seyhan AA, El-Deiry WS. "Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer." International Journal of Molecular Sciences, vol. 24, no. 4, 2023. |
May MS, Jamison JK, Wong W, Michel A, Raufi AG, Neugut AI, Manji GA. "Smoking is not associated with lung metastasis in pancreatic cancer." Cancer investigation, 2023, pp. 1-4. |
Madka V, De La Cruz A, Pathuri G, Panneerselvam J, Zhang Y, Stratton N, Hacking S, Finnberg NK, Safran HP, Sei S, Glaze ER, Shoemaker R, Fox JT, Raufi AG, El-Deiry WS, Rao CV. "Oral administration of TRAIL-inducing small molecule ONC201/TIC10 prevents intestinal polyposis in the Apc (min/+) mouse model." American journal of cancer research, vol. 12, no. 5, 2022, pp. 2118-2131. |
Breakstone R, Almhanna K, Raufi A, Beard RE, Leonard KL, Renaud J, Kastura M, Dionson S, Wood R, Sturtevant A, Dipetrillo T, Olszewski A, Safran H. "The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318." American Journal of Clinical Oncology, vol. 45, no. 8, 2022, pp. 327-332. |
Manji GA, Van Tine BA, Lee SM, Raufi AG, Pellicciotta I, Hirbe AC, Pradhan J, Chen A, Rabadan R, Schwartz GK. "A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors." Clin Cancer Res , vol. 27, no. 20, 2021, pp. 5519-5527. |
Hsu A, Raufi AG. "Advances in Systemic Therapy for Gastric Cancer." Gastrointestinal Endoscopy Clinics of North America, vol. 31, no. 3, 2021, pp. 607-623. |
May M, Raufi AG, Sadeghi S, Chen K, Iuga A, Sun Y, Ahmed F, Bates S, Manji GA. "Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature." The oncologist, vol. 26, no. 8, 2021, pp. 640-646. |
Raufi,Alexander G. Liguori,Nicholas R. Carlsen,Lindsey Parker,Cassandra Hernandez Borrero,Liz Zhang,Shengliang Tian,Xiaobing Louie,Anna Zhou,Lanlan Seyhan,Attila A. El-Deiry,Wafik S. "Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma." Frontiers in Pharmacology, vol. 12, no. 3166, 2021, pp. 751568. |
Raufi AG, Breakstone R, Leonard K, Charpentier K, Beard R, Renaud J, Cavanaugh L, Sturtevant A, MacKinnon K, Almhanna K, Olszewski A, Safran HP. "Adjuvant FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer: A Brown University Oncology Research Group Phase II Study (BrUOG295)." American Journal of Clinical Oncology, vol. 43, no. 12, 2020, pp. 857-860. |
Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA. "BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects." Cancer management and research, vol. 12, 2020, pp. 2731-2742. |
Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, Jhaveri A, Ferrarini I, Lee Y, Parker C, Zhang Y, Borsuk R, Chang WI, Honeyman JN, Tavora F, Carneiro B, Raufi A, Huntington K, Carlsen L, Louie A, Safran H, Seyhan AA, Tarapore RS, Schalop L, Stogniew M, Allen JE, Oster W, El-Deiry WS. "ONC201 and imipridones: Anti-cancer compounds with clinical efficacy." Neoplasia, vol. 22, no. 12, 2020, pp. 725-744. |
"Slicing the Pie: Personalized medicine changing pancreatic cancer outcomes." HemOnc Today, 2020.
|
Raufi AG, May M, Greendyk RA, Iuga A, Ahmed F, Mansukhani M, Manji GA. "Spontaneous Regression and Complete Response to Immune Checkpoint Blockade in a Case of High-Grade Neuroendocrine Carcinoma." JCO precision oncology, vol. 4, 2020, pp. 1006-1011. |
Raufi AG, Wong W, Chen K, Iuga A, Ahmed F, Manji GA. "Sustained Partial Response to Inhibition of the Mitogen-Activated Protein Kinase and Autophagy Pathways in Combination With Immune Checkpoint Blockade in KRAS-Mutated Adenocarcinoma of the Small Bowel." JCO precision oncology, vol. 4, 2020, pp. 1122-1127. |
Hsu A, Chudasama R, Almhanna K, Raufi A. "Targeted therapies for gastroesophageal cancers." Annals of Translational Medicine, vol. 8, no. 17, 2020, pp. 1104. |
Raufi AG, Almhanna K. "Immune checkpoint inhibitors for esophageal cancer: are we moving in the right direction?." Annals of Translational Medicine, vol. 7, no. Suppl 3, 2019, pp. S102. |
Raufi AG, Manji GA, Chabot JA, Bates SE. "Neoadjuvant Treatment for Pancreatic Cancer." Seminars in oncology, vol. 46, no. 1, 2019, pp. 19-27. |
Marchi E, Raufi AG, O'Connor OA. "Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma." Hematology/oncology clinics of North America, vol. 31, no. 2, 2017, pp. 359-375. |
Raufi AG, Klempner SJ. "Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations." Journal of gastrointestinal oncology, vol. 6, no. 5, 2015, pp. 561-9. |
Klempner SJ, Raufi A, Ou SH. "Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning." Translational lung cancer research, vol. 4, no. 5, 2015, pp. 649-52. |
Yang W, Raufi A, Klempner SJ. "Targeted therapy for gastric cancer: molecular pathways and ongoing investigations." Biochimica et biophysica acta, vol. 1846, no. 1, 2014, pp. 232-7. |
Year | Degree | Institution |
---|---|---|
2013 | MD | The Warren Alpert Medical School of Brown University |
2008 | BS | Brown University |
The Miriam Hospital/Rhode Island Hospital
The LIfespan Cancer Institute
The Warren Alpert Brown Medical School
Legorreta Cancer Center at Brown University
Doctor of Medicine | - | #MD16571 | |
American Board of Internal Medicine, Medical Oncology | - | ||
American Board of Internal Medicine | - |
Assistant Professor of Medicine. Warren Alpert Medical School of Brown University, - |
Director of Gastrointestinal Clinical Trials Lifespan Cancer Institute. - |